Publication: Immunoexpression of the CD30 ligand-CD30 and IL-6-IL-6R signals in thyroid autoimmune diseases
Loading...
Date
2006
Authors
Ruggeri, R.M. ; Barresi, G. ; Sciacchitano, S. ; Trimarchi, F. ; Benvenga, S. ; Trovato, M.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
To elucidate the role of Th2 cytokines in
autoimmune thyroid diseases, we have studied by
immunohistochemistry the expression of two Th2
ligand/receptor systems (CD30-L/CD30 and IL-6/IL-6R)
in goitrous Graves’ disease (GD) and Hashimoto’s
thyroiditis (HT).
A total number of 50 nodular goiters (NG),
including 10 GD showing a lymphoid aggregate grade I,
30 HT 8 of which had a lymphoid aggregate of grade I,
12 of grade II and 10 grade III, and 10 colloid goiters
have been evaluated. In addition, 5 normal thyroids were
included in the study as controls.
Reactivity of ligand and cognate receptor of both
CD30-L/CD30 and IL-6/IL-6R pathways was observed
in a greater proportion of GD, compared to HT
(P<0.005). In HT, the expression of CD30-L/CD30
system was detected more frequently than IL-6/IL-6R
(P<0.05) and showed an inverse correlation with the
grade of lymphoid aggregate, whereas IL-6/IL-6R
correlated positively with lymphocyte infiltration
(P<0.05).
Based on our results concerning a dominance of Th2
cytokines in GD, we postulate that CD30-L/CD30 and
IL-6/IL-6R systems could play a major role in the
pathogenesis of GD. However, the expression of CD30L/CD30 and IL-6/IL-6R in HT suggests that Th2
mechanisms are involved also in tissue damage of HT.
The two systems could contribute to drive the
autoimmune response skewing toward a Th2 phenotype
and this appears to be correlated with the lymphoid
aggregate grade.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.